LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

TransMedics Group Inc

Suletud

SektorTervishoid

71.25 2.71

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

69.55

Max

73.75

Põhinäitajad

By Trading Economics

Sissetulek

-98M

7.3M

Müük

13M

174M

P/E

Sektori keskmine

15.453

49.888

Aktsiakasum

0.3

Kasumimarginaal

4.206

Töötajad

898

EBITDA

-7.3M

25M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+71.66% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

-1B

2.3B

Eelmine avamishind

68.54

Eelmine sulgemishind

71.25

Uudiste sentiment

By Acuity

51%

49%

266 / 344 Pingereas Healthcare

TransMedics Group Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 19:15 UTC

Suurimad hinnamuutused turgudel

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Võrdlus sarnastega

Hinnamuutus

TransMedics Group Inc Prognoos

Hinnasiht

By TipRanks

71.66% tõus

12 kuu keskmine prognoos

Keskmine 119.63 USD  71.66%

Kõrge 175 USD

Madal 63 USD

Põhineb 9 Wall Streeti analüütiku instrumendi TransMedics Group Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

6

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

266 / 344 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat